Detalhe da pesquisa
1.
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Blood
; 137(25): 3495-3506, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33598678
2.
Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism.
Nucleic Acids Res
; 48(22): 12727-12745, 2020 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33245769
3.
The rise of apoptosis: targeting apoptosis in hematologic malignancies.
Blood
; 132(12): 1248-1264, 2018 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30012635
4.
Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.
Acta Oncol
; 59(12): 1547-1551, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32970500
5.
Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study.
Eur J Cancer
; 99: 86-96, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29935491
6.
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
JCI Insight
; 3(19)2018 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30282833
7.
A novel chemosensitivity profiling platform for small acute lymphoblastic leukemia cell populations.
Leuk Lymphoma
; 56(7): 2208-11, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25530346